|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||311.00 - 312.82|
|52 Week Range||261.65 - 342.50|
|PE Ratio (TTM)||10.86|
|Expense Ratio (net)||0.47%|
Broadcom made an unsolicited bid for Qualcomm early Monday. The $70 a share offer values the deal at a whopping $130 billion. Yahoo Finance's Alexis Christoforous and Jared Blikre discuss what are the odds this deal will get regulatory approval, and what it could mean for the chip industry.
The “Fast Money” traders share their final trades for the day including Bank of America, Nasdaq Biotechnology ETF, MSCI Emerging Markets ETF and Alphabet.
Better and faster care. It’s what we want from our doctors and healthcare providers. And new technology is finally starting to solve some of the most frustrating problems doctors and patients have. Yahoo Finance's Alexis Christoforous and Michael Keoni DeFranco, CEO of Lua, discuss.
The treasury secretary gave an ’absolute guarantee' that a tax overhaul would be signed into law by the end of the year. Yahoo Finance’s Alexis Christoforous, Dan Roberts, and Kevin Mahn, CIO of Hennion & Walsh Asset Management discuss whether or not investors should trust Mnuchin’s tax prediction.
Carter Worth, Cornerstone Macro, discusses how the health care sector is starting to heat up. The “Fast Money” traders weigh in.
Alan Valdes, Director of Floor Operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss Q3 earnings and if investors have gotten too optimistic.
CNBC's Meg Tirrell reports on California's proposed bill requiring companies to give 60 days notice in advance when they plan to raise drug prices over a certain threshold.
Shares of large-cap biotechnology stocks as a group and as represented by the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) rallied on Thursday as a broader risk-on feel came back to the world of U.S. equities. As regular readers of this column know, higher-volatility groups of stocks and in particular biotechnology in my eye are better traded using an ETF to represent the group thematically. While I continue to like biotechnology and the IBB ETF thematically, through a multi-month lens, I don’t so much like to a) buy them at the top end of their trading ranges and b) don’t like all stocks in this space at any price.
iShares Trust – iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) generated a below-average return on equity of 11.11% in the past 12 months, while its industry returned 11.73%. An investor may attributeRead More...
Loxo's deal with Bayer had a bigger impact on the biotech sector than you'd expect, an industry observer said.
If someone had told you at the beginning of the year that the Republican-controlled Congress was going to try and fail to repeal and replace the Affordable Care Act (ACA) multiple times during 2017, you probably wouldn’t have believed them. You might think that this uncertainty would have taken a bearish toll on healthcare stocks, but you’d be wrong in most cases. Many healthcare stocks are keeping pace with, or outperforming, the S&P 500.
A big biotechnology exchange traded fund will soon get a lower price tag. BlackRock Inc. (NYSE: BLK ), the parent company of iShares, the world's largest ETF sponsor, announced a share split for the iShares ...
Shares of Regeneron Pharmaceuticals Inc. rallied 2.6% in premarket trade Wednesday, after the biotechnology company reported third-quarter profit and revenue that rose above expectations. Net income increased ...
Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.
Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.
Yesterday, Celgene Corporation (NASDAQ:CELG) caught a downgrade and the stock fell 4% on the headline. To do this, I use CELG options instead of trading its underlying equity. Click to Enlarge Fundamentally, Celgene is not cheap.